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Introduction
Ahigh prevalence of thyroid gland dysfunctionhas been reported in hepatitis C virus (HCV)
infected patients before and after interferon-alfa (IFN|-
α|) therapy and some data also show a high prevalence
of antiHCV antibody in patients with autoimmune
thyroiditis (1). But this prevalence is very low in
patients infected with hepatitis B virus (HBV) (2).
IFN-α has important effects on the cell mediated
immunity such as activation of macrophages,
regulation natural killer cells and cytotoxic T cells
activity. Furthermore, it has a relationship with
cytokine production and major histocompatibility
complex (MHC) system. Anti viral effects of IFN-α
was discovered in 1957 (1). The interferons are
classified based on structural and biochemical
characters into four groups: α, |β, |δ|, and |γ|. Despite a
broad range of immunological effects, the role of IFN-
α in the pathogenesis of autoimmune thyroid diseases
remains uncertain (1). Fentiman firstly reported the
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Thyroid Dysfunction in Patients with Chronic Viral Hepatitis B and C
during Alpha Interferon Therapy
Background and Aims: Thyroid dysfunction has been reported in patients with chronic viral hepatitis B and C before and
after alpha interferon (IFN-|α|) therapy and a high prevalence of anti hepatitis C virus (anti-HCV) antibodies in patients
with autoimmune thyroiditis has been shown. The aim of this study was to determine the rate of thyroid dysfunction in
hepatitis B virus (HBV) and HCV infected patients during IFN-α| therapy and to compare them.
Methods: In this prospective study, many patients with hepatitis B and C who had undergone IFN-α| therapy were
studied. Eighteen cases of HBV and fifty-eight cases of HCV entered the study. Thyroid weight measurement, thyroid
functional test and anti-thyroid antibodies assay were performed when the study initiated and were repeated after two,
four and six months. 
Results: Thyroid dysfunction was not seen in the HBV group. Only 6 (10.3%) cases of thyroid dysfunction were seen in
HCV group (5 hypothyroidism and 1 thyroiditis). Four cases of them had positive levels of thyroid peroxidase antibody
(Tpo Ab) before IFN-α| therapy. In the HBV group, only 1 (5.5%) patient had positive levels of Tpo Ab. However, at the
end of the study, 3 (16.7%) patients had positive levels of Tpo Ab. In the HCV group, at the beginning of the treatment,
8 (13.8%) patients had Tpo Ab; but at the end of study, 14 (24.1%) cases became positive. During the IFN-α| therapy,
mean weight of thyroid gland in both HCV and HBV groups were significantly increased (P<0.005 and P<0.001
respectively). There were not any relationships between thyroglobulin (Tg) Ab levels and duration of IFN-α| therapy. 
Conclusions: Patients with HCV are more susceptible to thyroid dysfunction during IFN-α| therapy than patients with
HBV. As a result, screening of thyroid gland function and Tpo Ab titers in all patients with HCV before and during IFN-
α| therapy may be necessary. However, this needs further studies in HBV patients.
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occurrence of hypothyroidism after IFN-α therapy in
1985 (3). This fact was followed by multiple studies
and prevalence of thyroid gland dysfunction was
reported to be about 11% in 1991 (1).
Several studies not only expressed the prevalence
of thyroid dysfunction but also assessed antithyroid
antibodies production in these patients. They
showed the elevation of thyroid peroxidase antibody
(Tpo Ab) and thyroglobulin (Tg) Ab levels in
patients during IFN-α therapy compared with the
normal population (2, 4, 5). In Iran, viral hepatitis is
an important and common disease. The prevalence
of HBV and HCV based on antibodies assay are
about 2-3% and 0.3%, respectively (6).
Due to the widespread use of IFN-α in the
treatment of these patients, recognition of adverse
effects of this drug is important. The aim of this
prospective study was to determine the rate of
thyroid dysfunction in HBV and HCV patients,
during IFN-α therapy in Tehran Hepatitis Center
and to compare them. As we know this study is done
for the first time in Iran. 
Materials and Methods
This interventional study was performed on 76
patients with hepatitis (58 HCV and 18 HBV) in
Tehran Hepatitis Center, between March 2002 and
May 2003. Our sampling methods were according
to a study by Imigawa et al. (5).
All patients signed an inform consent form. The
Ethical Committee of Tehran University of Medical
Sciences approved the study protocol.
Confirmatory tests for anti HCV (enzyme-linked
immunosorbant assay ELISA) positive patients were
recombinant immunoblot assay (RIBA) and HCV
RNA (polymerase chain reaction PCR). If HCV
RNA was positive, qualitative PCR for the
determination of HCV genotype was performed. If
genotypes 1b or 1a were found, liver biopsy was
recommended. However, if genotype 3a was found,
IFN-α therapy without liver biopsy was started.
Also in the HBV group, following tests were
performed: hepatitis B surface antigen (HBsAg),
hepatitis B e antigen (HBeAg), hepatitis B surface
antibody (HBsAb), hepatitis B e antibody (HBeAb)
and hepatitis B core antibody (HBcAb). Further
studies included qualitative and viral loading PCR
for the detection of HBV DNA. In these patients,
indications of liver biopsy were as follows: positive
HBeAg and elevation of liver function test. Before
the start of the treatment in both HCV and HBV
patients, other studies including liver sonography,
platelet count and serum protein electrophoresis
were performed. Treatment started only in
non cirrhotic patients with sufficient status. All
serologic tests were performed in Tehran Blood
Transfusion Organization.
An endocrinologist visited the patients and
reviewed history and thyroid functional test and
performed thyroid physical examination. If the
previous studies were unremarkable, the patient
entered the research. These patients were
re evaluated in 2, 4, 6 month intervals. In all
patients we measured serum levels of T3 and T4
using RIA with a normal range of 80-160 ng/dl and
5-12 µg/dl, respectively.
Thyroid stimulating hormone (TSH)
measurements were made via immunoradiometric
assay (IRMA) with a normal range of 0.3-3 mIu.
Tpo Ab and Tg Ab were assayed via ELISA (DRG-
test, Germany). Tpo Ab positive titers were
considered those higher than 50 mIu and in Tg Ab
higher than 100 mIu. Thyroid weight was assessed
by physical examination. Statistical analyses were
performed using SPSS, ver 11.0. Variables were
compared by means of statistical repeated measure
and ANOVA. For statistical analysis, we used
Friedman test which is a non-parametric statistical
test in order to detect differences in treatments
across multiple test attempts. 
Results
Seventy six patients, 15 (19.7%) women and 61
(80.31%) men, were included in this study
(eighteen patients (23.6%) with HBV (6 women
and 12 men; mean age± SD: 27.7±4.7 yr) and fifty
eight patients (76.4%) with HCV (9 women and 49
men; mean age± SD: 37.9± 10.97 yr)). During the
study, thyroid gland dysfunction occurred in six
HCV patients (Table 1). As Table 1 shows, thyroid
dysfunction occurred in 10.3 % of HCV patients. 
Although thyroid function of all patients were
normal before the IFN|-α therapy, three patients
showed thyroid dysfunction two months after the
treatment was initiated and three cases developed
thyroid dysfunction four months after the therapy.
Amir Ziaee et al.
1 28 Male 2 Hypo
2 34 Male 4 Hypo
3 57 Female 4 Hypo
4 59 Male 2 Hypo
5 44 Male 2 Hyper
6 19 Male 4 Hypo
Patient Age Sex Dysfunctional occurrenceTime (months)
Thyroid gland
dysfunction
Table 1. Characters of six HCV patients with occur-
rence of thyroid gland dysfunction during the IFN
therapy.
Five of these 6 patients became hypothyroid and the
remaining case developed thyroiditis-associated
thyrotoxicosis which was confirmed by radioactive
iodine absorption. In the HBV group, thyroid
dysfunction was not seen. Thyroid tests results in six
patients with thyroid dysfunction are shown in
Table 2. Before treatment, positive levels of Tpo Ab
were found in 8 (13.8%) patients with HCV which
increased to 14 (24.1%) cases after 6 months.
According to the results, before IFN-α therapy,
positive levels of Tpo Ab were found in four HCV
patients but increased to five cases after therapy
(Table 2). Before and after the treatment, positive
levels of Tg Ab were found in 5 (8.6%) and 8
(13.8%) cases, respectively. In patients with HBV,
no relationship was found between Tpo and Tg Ab
levels and duration of IFN-α therapy.
Post-treatment TSH levels in patients with HCV
increased significantly compared to pre-treatment
values (P<0.02) while it decreased in HBV patients;
however, this decrease was not significant (Table 3).
Nonetheless, TSH levels in euthyroid HCV patients
did not change significantly at the end of the
treatment. Mean thyroid gland weight in HBV and
HCV patients significantly increased after treatment
compared to before treatment (P<0.001 and
P<0.005, respectively) (Table 3). Mean age of HCV
and HBV patients are shown in Table 3.
Discussion
IFNs have been shown to modulate immune
responses by increasing natural killer cell activity,
enhancing cytotoxic lymphocyte maturation and
increasing HLA class I
expression in infected cells (7).
Also, IFNs modulate the
suppressor activity of T
lymphocytes (4). However,
the role of IFN-α in the
pathogenesis of autoimmune
thyroid diseases remains
uncertain (8). IFN-α directly
inhibits production, release
and metabolism of thyroid
hormones. Not only
i m m u n o m o d u l a t i o n
properties of IFN-α have
crucial roles in pathogenesis,
but also genetic
predisposition factors are
important (9). Following the
initial reporting of
hypothyroidism after IFN-α
therapy by Fentiman and coworkers in 1985, many
other patients with this complication were reported
(1, 3, 5, 6, 10). In previous reports, the prevalence of
thyroid gland dysfunction varied markedly ranging
from 3.4% to 31.4% (4, 5). Differences in
geographical distribution, genetic variability in the
populations studied and even environmental factors
such as iodine intake or virus infection could play a
major role in the development of thyroid
dysfunction after IFN-α therapy (9). In previous
studies, the prevalence of thyroid dysfunction
following IFN-α therapy was reported to be 8-12%
and in our study was reported to be 10.4%.
Therefore, it is in accordance with other studies
from other countries (1, 11).
There was a significant difference between our
study and other studies in HBV patients' age which
could be related to the vertical transmission route in
Iran. However HCV patients' age in our study was
lower than other similar studies (6).
In other studies, it was found that female sex was
a risk factor for developing thyroid dysfunction in
HCV patients (12). Our study was in contrast to this
finding. On the other hands, our results were similar
to a study by Lisker-Melman et al. (8). In the present
study, after the start of IFN-α therapy, Tpo Ab
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Patient 1. before therapy 9 140 1 27 (+) 120 (+) 230
2 months after therapy 4.5 64 37 21 (+) 120 (+) 230
Patient 2. before therapy 8.5 128 0.9 28 (+) 150 (+) 200
4months after therapy 3.5 80 45 17 (+) 200 (+) 300
Patient 3. before therapy 10.1 147 0.7 30 (+) 100 (+) 150
4months after therapy 4.3 87 40 21 (+) 200 (+) 200
Patient 4. before therapy 9.6 139 31 26 (+) 140 -
2 months after therapy 3.2 90 36 20 (+) 540 -
Patient5. before therapy 10.9 160 0.3 30 (-) <50 (-) <100
2 months after therapy 13.3 253 0.1 37 (-) <50 (-) <100
Patient6. before therapy 8.5 100 0.7 28 (-) <50 (-) <100
4months after therapy 4.5 86 30 22 (+) 150 (+) 150
Table 2. Thyroid test results in six HCV patients with occurrence of thyroid
gland dysfunction during IFN therapy.
T4 (|µ|g /dl) T3 (ng/dl) TSH (mIu) T3Ru (%) Tpo-Abs (mIu) Tg-Abs (mIu)
HCV 37.9±10.9 0.81±0.7 0.9±0.3a 20.6±2.3 20.8±2.1b
HBV 27.7±4.7 1.7±0.6 1±0.4 19.3±2.1 20.36±2.4c
Patients Mean age (yr)
TSH (mIu) Thyroid gland weight (g)
Before After Before After
Table 3. TSH levels and mean of thyroid gland
weight in HCV and HBV patients before and after
treatment.
a: P<0.02, b: P<0.005, c: P<P<0.001
increased from 13.8% to 24.1%. Our overall results
are in agrreement with other studies (3, 4, 10, 12).
The effect of Tg Ab in the development of
thyroid dysfunction is lower than Tpo Ab and also
in the present study, after the start of IFN-α therapy,
Tg Ab increased from 8.6% to 13.8% which showed
no significant relationship and are in agreement
with other similar studies (2, 4, 5, 10). In our study,
thyroid dysfunction was present in 6 (10.2 %)
patients with HCV and hypothyroidism and
thyroiditis were found in five and one cases,
respectively. Thyroid dysfunction induced by IFN-α
therapy was not present in any of the 18 patients
with HBV. Before treatment, positive levels of Tpo
Ab and Tg Ab were found in 1 (5.5%) and 1
(5.5%). During the therapy, positive levels of Tpo
Ab and Tg Ab were found in 3 (16.7%) and 2
(11%) cases of HBV patients respectively. However,
their relationship was not significant.
Fernandez et al. found positive levels of Tpo Ab
and Tg Ab in 5 % and 3 % of patients with HBV
and revealed a 3 % thyroid dysfunction during the
therapy (sample size: 41 patients) (2). In a study by
Deutsch et al. 7 (4 %) of the 170 patients with HBV
revealed thyroid gland dysfunction (13). In another
study by Preziati et al. on 51 patients with HBV who
underwent IFN-α therapy, initially positive levels of
Tpo Ab and Tg Ab were found in zero and 5 (9.8 %)
patients, respectively (4).
After the start of the treatment, only 27 cases were
followed up. Positive levels of Tpo Ab and Tg Ab were
found in 11.1 % and 14.8 % of patients, respectively.
In this study, hypothyroidism was not found while
hyperthyroidism was found in one patient (4).
According to previous studies, patients with HCV are
more susceptible to thyroid dysfunction than those
with HBV after treated with IFN-α.
In some studies, it was suggested that screening
tests before the IFN-α therapy were not necessary
and further studies should be performed if clinically
indicated (2, 5). There was a significant difference
between the prevalence of HBV and HCV thyroid
dysfunction. In the present study, thyroid gland
dysfunction was not found in any of the HBV
patients compared with other studies. However, it
seems that  this discrepancy was solved through an
increased sample size in privious studies. Our study
exclusively revealed a relationship between thyroid
gland weight and duration of IFN-α therapy. As we
observed, there was a significant raise of thyroid
weight in the course of time. This change is most
probably due to the irregularity of thyroid hormone
synthesis or release pathway. However, in long-term
follow up of the patients, thyroid goiter may be
found. Physical examination is less sensitive
compared to thyroid weight suggested by
ultrasound.
According to our results in HCV patients, we
recommend the assessment of thyroid function tests
and Tpo Ab assay before the treatment and their re-
evaluation in 2 to 3 month intervals. Further research
will determine the management of HBV patients.
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